Compound 42: Pharmacological Data for a Dual URAT1/GLUT9 Inhibitor

Compound 42 demonstrated a urate-lowering efficacy ratio of 88.76% in acute hyperuricemia mice, significantly superior to Lesinurad (39.02%). The dataset likely contains pharmacological metrics for this novel pyrrole acylsulfonamide, including IC50 values for URAT1 (2.81 ± 0.40 μM) and GLUT9 (12.53 ± 1.33 μM), pharmacokinetics, and ligand efficiency. Author Zhenqian Wang uploaded the data to figshare in April 2026.

Use Cases

• Analyze urate-lowering efficacy based on the reported decrease ratio of 88.76%
• Compare inhibitor potency based on IC50 values for URAT1 and GLUT9
• Evaluate pharmacokinetic properties based on reported half-life (T1/2 = 5.55 h) and bioavailability (F = 51.3%)
• Assess ligand efficiency based on the reported LE = 0.44

Strengths

• Contains specific efficacy metrics, including a urate decrease ratio of 88.76%
• Includes precise IC50 values for key targets URAT1 (2.81 ± 0.40 μM) and GLUT9 (12.53 ± 1.33 μM)
• Reports pharmacokinetic parameters (T1/2 = 5.55 h, F = 51.3%) and ligand efficiency (LE = 0.44)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The dataset is very small (4.0 KB), indicating limited scope

Provenance

Source

figshare

Freshness

Last updated 2026-04-17 23:29:33